AIGH Capital Management LLC Purchases Shares of 758,328 Biodesix, Inc. $BDSX

AIGH Capital Management LLC acquired a new position in shares of Biodesix, Inc. (NASDAQ:BDSX) in the first quarter, Holdings Channel.com reports. The institutional investor acquired 758,328 shares of the company’s stock, valued at approximately $10,996,000. Biodesix accounts for approximately 1.5% of AIGH Capital Management LLC’s investment portfolio, making the stock its 19th largest position. AIGH Capital Management LLC owned about 0.08% of Biodesix as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of BDSX. Cetera Investment Advisers bought a new position in shares of Biodesix in the fourth quarter valued at approximately $68,000. Thompson Davis & CO. Inc. purchased a new position in shares of Biodesix during the first quarter valued at approximately $170,000. Millennium Management LLC bought a new stake in Biodesix during the third quarter worth $113,000. Oracle Investment Management Inc. bought a new stake in Biodesix during the third quarter worth $113,000. Finally, DRW Securities LLC bought a new stake in Biodesix during the fourth quarter worth $105,000. 20.96% of the stock is owned by hedge funds and other institutional investors.

Biodesix Price Performance

BDSX opened at $20.15 on Thursday. The firm has a market cap of $208.75 million, a P/E ratio of -4.96 and a beta of 0.53. The firm has a 50-day moving average of $16.52 and a 200 day moving average of $13.50. The company has a debt-to-equity ratio of 5.09, a quick ratio of 2.82 and a current ratio of 2.82. Biodesix, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $24.92.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.32. The business had revenue of $25.55 million during the quarter, compared to the consensus estimate of $23.12 million. Biodesix had a negative net margin of 33.26% and a negative return on equity of 2,101.40%. On average, research analysts expect that Biodesix, Inc. will post -2.91 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on BDSX shares. Canaccord Genuity Group raised their price objective on Biodesix from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. HC Wainwright began coverage on shares of Biodesix in a research note on Monday, June 15th. They issued a “buy” rating and a $26.00 target price for the company. Weiss Ratings upgraded shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, June 12th. Finally, Roth Capital started coverage on shares of Biodesix in a report on Wednesday, June 24th. They issued a “buy” rating and a $32.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Biodesix has an average rating of “Moderate Buy” and a consensus target price of $28.33.

Biodesix Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.